Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease: A systematic review

Andrew Dawson, Nadeeka N. Dissanayaka, Andrew Evans, Antonio Verdejo-Garcia, Trevor T.J. Chong, Giuseppe Frazzitta, Davide Ferrazzoli, Paola Ortelli, Murat Yücel, Adrian Carter

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Dopaminergic medication can induce severe addictive behaviours (e.g., pathological gambling) in susceptible Parkinson's disease (PD) patients. It is still unknown which particular neurocognitive processes become exacerbated or dysfunctional in PD patients with addictive behaviours. We sought to systematically review the relevant literature to identity potential neurocognitive correlates of medication-induced addictive behaviours in PD. We framed our review around neurocognitive processes central to four dominant accounts of substance addiction: ‘aberrant learning’, ‘incentive sensitization’, ‘impulsivity to compulsivity’ and ‘impaired response inhibition and salience attribution’. Searches of the PubMed and Scopus databases were completed on June 23, 2017. To be included, studies were required to involve: (a) medicated PD patients, without a history of deep brain stimulation, with and without addictive behaviours; (b) a reward-related or decision-making task; and (c) statistical comparison of addictive and non-addictive groups’ ‘on’ medication performance on the task(s). Studies were summarised qualitatively with statistically significant (p<.05) group differences and effect sizes (Cohen's d) highlighted. 35 studies were included. Findings showed that the extant literature is highly heterogeneous. The domains of reward and punishment learning, reflection impulsivity and disadvantageous decision-making exemplify this. More homogeneity exists in domains in which (a) neurocognitive dysfunction is not apparent (motor control, cognitive/attentional flexibility and cognitive control) or (b) typical neurocognitive processes appear exacerbated by medication (reward motivation and choice impulsivity). Future large-scale neurocognitive studies are still required to develop our scientific understanding of addictive behaviours in PD and aid their clinical treatment and prediction.

Original languageEnglish
Pages (from-to)561-578
Number of pages18
JournalEuropean Neuropsychopharmacology
Volume28
Issue number5
DOIs
Publication statusPublished - May 2018

Keywords

  • Addiction
  • Cognition
  • Decision-making
  • Parkinson's disease
  • Reward

Cite this

Dawson, Andrew ; Dissanayaka, Nadeeka N. ; Evans, Andrew ; Verdejo-Garcia, Antonio ; Chong, Trevor T.J. ; Frazzitta, Giuseppe ; Ferrazzoli, Davide ; Ortelli, Paola ; Yücel, Murat ; Carter, Adrian. / Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease : A systematic review. In: European Neuropsychopharmacology. 2018 ; Vol. 28, No. 5. pp. 561-578.
@article{7593a753501146f1896ca1919add1ff6,
title = "Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease: A systematic review",
abstract = "Dopaminergic medication can induce severe addictive behaviours (e.g., pathological gambling) in susceptible Parkinson's disease (PD) patients. It is still unknown which particular neurocognitive processes become exacerbated or dysfunctional in PD patients with addictive behaviours. We sought to systematically review the relevant literature to identity potential neurocognitive correlates of medication-induced addictive behaviours in PD. We framed our review around neurocognitive processes central to four dominant accounts of substance addiction: ‘aberrant learning’, ‘incentive sensitization’, ‘impulsivity to compulsivity’ and ‘impaired response inhibition and salience attribution’. Searches of the PubMed and Scopus databases were completed on June 23, 2017. To be included, studies were required to involve: (a) medicated PD patients, without a history of deep brain stimulation, with and without addictive behaviours; (b) a reward-related or decision-making task; and (c) statistical comparison of addictive and non-addictive groups’ ‘on’ medication performance on the task(s). Studies were summarised qualitatively with statistically significant (p<.05) group differences and effect sizes (Cohen's d) highlighted. 35 studies were included. Findings showed that the extant literature is highly heterogeneous. The domains of reward and punishment learning, reflection impulsivity and disadvantageous decision-making exemplify this. More homogeneity exists in domains in which (a) neurocognitive dysfunction is not apparent (motor control, cognitive/attentional flexibility and cognitive control) or (b) typical neurocognitive processes appear exacerbated by medication (reward motivation and choice impulsivity). Future large-scale neurocognitive studies are still required to develop our scientific understanding of addictive behaviours in PD and aid their clinical treatment and prediction.",
keywords = "Addiction, Cognition, Decision-making, Parkinson's disease, Reward",
author = "Andrew Dawson and Dissanayaka, {Nadeeka N.} and Andrew Evans and Antonio Verdejo-Garcia and Chong, {Trevor T.J.} and Giuseppe Frazzitta and Davide Ferrazzoli and Paola Ortelli and Murat Y{\"u}cel and Adrian Carter",
year = "2018",
month = "5",
doi = "10.1016/j.euroneuro.2018.03.012",
language = "English",
volume = "28",
pages = "561--578",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "5",

}

Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease : A systematic review. / Dawson, Andrew; Dissanayaka, Nadeeka N.; Evans, Andrew; Verdejo-Garcia, Antonio; Chong, Trevor T.J.; Frazzitta, Giuseppe; Ferrazzoli, Davide; Ortelli, Paola; Yücel, Murat; Carter, Adrian.

In: European Neuropsychopharmacology, Vol. 28, No. 5, 05.2018, p. 561-578.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease

T2 - A systematic review

AU - Dawson, Andrew

AU - Dissanayaka, Nadeeka N.

AU - Evans, Andrew

AU - Verdejo-Garcia, Antonio

AU - Chong, Trevor T.J.

AU - Frazzitta, Giuseppe

AU - Ferrazzoli, Davide

AU - Ortelli, Paola

AU - Yücel, Murat

AU - Carter, Adrian

PY - 2018/5

Y1 - 2018/5

N2 - Dopaminergic medication can induce severe addictive behaviours (e.g., pathological gambling) in susceptible Parkinson's disease (PD) patients. It is still unknown which particular neurocognitive processes become exacerbated or dysfunctional in PD patients with addictive behaviours. We sought to systematically review the relevant literature to identity potential neurocognitive correlates of medication-induced addictive behaviours in PD. We framed our review around neurocognitive processes central to four dominant accounts of substance addiction: ‘aberrant learning’, ‘incentive sensitization’, ‘impulsivity to compulsivity’ and ‘impaired response inhibition and salience attribution’. Searches of the PubMed and Scopus databases were completed on June 23, 2017. To be included, studies were required to involve: (a) medicated PD patients, without a history of deep brain stimulation, with and without addictive behaviours; (b) a reward-related or decision-making task; and (c) statistical comparison of addictive and non-addictive groups’ ‘on’ medication performance on the task(s). Studies were summarised qualitatively with statistically significant (p<.05) group differences and effect sizes (Cohen's d) highlighted. 35 studies were included. Findings showed that the extant literature is highly heterogeneous. The domains of reward and punishment learning, reflection impulsivity and disadvantageous decision-making exemplify this. More homogeneity exists in domains in which (a) neurocognitive dysfunction is not apparent (motor control, cognitive/attentional flexibility and cognitive control) or (b) typical neurocognitive processes appear exacerbated by medication (reward motivation and choice impulsivity). Future large-scale neurocognitive studies are still required to develop our scientific understanding of addictive behaviours in PD and aid their clinical treatment and prediction.

AB - Dopaminergic medication can induce severe addictive behaviours (e.g., pathological gambling) in susceptible Parkinson's disease (PD) patients. It is still unknown which particular neurocognitive processes become exacerbated or dysfunctional in PD patients with addictive behaviours. We sought to systematically review the relevant literature to identity potential neurocognitive correlates of medication-induced addictive behaviours in PD. We framed our review around neurocognitive processes central to four dominant accounts of substance addiction: ‘aberrant learning’, ‘incentive sensitization’, ‘impulsivity to compulsivity’ and ‘impaired response inhibition and salience attribution’. Searches of the PubMed and Scopus databases were completed on June 23, 2017. To be included, studies were required to involve: (a) medicated PD patients, without a history of deep brain stimulation, with and without addictive behaviours; (b) a reward-related or decision-making task; and (c) statistical comparison of addictive and non-addictive groups’ ‘on’ medication performance on the task(s). Studies were summarised qualitatively with statistically significant (p<.05) group differences and effect sizes (Cohen's d) highlighted. 35 studies were included. Findings showed that the extant literature is highly heterogeneous. The domains of reward and punishment learning, reflection impulsivity and disadvantageous decision-making exemplify this. More homogeneity exists in domains in which (a) neurocognitive dysfunction is not apparent (motor control, cognitive/attentional flexibility and cognitive control) or (b) typical neurocognitive processes appear exacerbated by medication (reward motivation and choice impulsivity). Future large-scale neurocognitive studies are still required to develop our scientific understanding of addictive behaviours in PD and aid their clinical treatment and prediction.

KW - Addiction

KW - Cognition

KW - Decision-making

KW - Parkinson's disease

KW - Reward

UR - http://www.scopus.com/inward/record.url?scp=85045263363&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2018.03.012

DO - 10.1016/j.euroneuro.2018.03.012

M3 - Article

VL - 28

SP - 561

EP - 578

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 5

ER -